Poolbeg has announced the publication of a peer-reviewed paper of the POLB 001 LPS human challenge trial in the journal Frontiers in Immunology. Key findings from the paper include: (i) POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers; (ii) POLB 001 was safe and well tolerated across all dose levels; and (iii) study confirms POLB 001 potently inhibits p38 MAPK driven cytokine responses. Importantly, the publicati ....
